The CNS Disease Biology Group is seeking a motivated student for an in vivo neuroscience internship with Alkermes that will help further our drug discovery efforts. The candidate should have experience in small rodent intracranial surgeries with an interest to apply these skills to problems in translational biology. The position will involve developing surgical techniques to be used in preclinical behavioral assays. The work will focus on a variety of preclinical assays and may involve in vivo electrophysiology, optogenetics, and/or behavioral pharmacology.
This is a good position for students who are interested in neuroscience/ biology and/or looking to learn more about what a career in drug discovery would entail.
Qualifications
BASIC QUALIFICATIONS:
Minimum education and experience requirements:
- 3+ years of undergraduate experience, masters or graduate experience is preferred. Strong, knowledge of biological systems and an interest in learning more about biology and neuroscience
Technical skills
- Small rodent intracranial surgery (survival)
- Animal handling
- Behavioral testing
- An interest in biology.
Personal skills
- The ability to work well with others to accomplish specific goals and to effectively communicate with project team members and managers is essential.
- Good presentation and oral/written communications skills which will be applied to presentations, documentation of work, and manuscript preparation as needed.
- The successful candidate will have outstanding initiative, be highly motivated to drive our science forward, learn new techniques and procedures, and be able to effectively conceive and develop complex analysis pipelines in diverse areas
PREFERRED QUALIFICATIONS:
- Has experience with in vivo electrophysiology
- Has experience with optogenetics
The candidate will be expected to work in an office setting at a computer for 8 hours a day
About Us
Why join Team Alkermes?
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, headquartered in Ireland with U.S. locations in Massachusetts and Ohio, we are committed to pursuing great science, driven by deep compassion to make a real impact in the lives of patients. Alkermes has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for various neurological disorders, including narcolepsy.
Beyond our important mission of developing medicines to address unmet patient needs, we actively seek to foster a culture of diversity, inclusion and belonging throughout our business. We strive to ensure that all voices are respected and valued, recognizing that our diversity of thought, background and perspective makes us stronger. We are proud to have been recognized as an employer of choice by many national organizations, including being certified as a Great Place to Work in the U.S. in 2024, honored as a Healthiest Employer in both Ohio and Massachusetts in 2023, a Best Place for Working Parents in 2023, and to have received the Bell Seal at the Platinum level for Workplace Mental Health by Mental Health America for three consecutive years (2021-2023).
Alkermes, Inc. is an equal employment opportunity employer and does not discriminate against any qualified applicant or employee because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, gender expression and identity, disability, genetic information, veteran status, military status, application for military service or any other characteristic protected by local, state or federal law. Alkermes also complies with all work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Alkermes is an E-Verify employer.
